Recherche avancée
22 sept.

Vous êtes ici : Accueil SPCMIB > Equipe SOMAB-RMN Biomédicale > RMN-Biomédicale

RMN Biomédicale, Production scientifique avant 2007

26. Usefulness of in vitro 1H magnetic resonance spectroscopy for the characterization of primary brain tumors: report of two cases. Sabatier J., Robert O., Delisle M.B., Malet-Martino M. Stereotactic and Functional Neurosurgery 2005, 83, 122-127.

25. Fluorine-19 or phosphorus-31 NMR spectroscopy: a suitable analytical technique for quantitative in vitro metabolic studies of fluorinated or phosphorylated drugs. Martino R., Gilard V., Desmoulin F., Malet-Martino M. Journal of Pharmaceutical and Biomedical Analysis 2005, 38, 871-891.

24. Cardio- and neurotoxicity of high-dose continuous 5-fluorouracil due to degradation compounds in the drug vials. Lukaschek J., Nufer M., Maurer D., Asanger M., Honegger H., Widmer L., Malet-Martino M., Legay R., Martino R. Journal of Clinical Oncology 2004, 22, 5022-5025.

23. Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuroconjugate of 5’-deoxy-5-fluorocytidine, namely 2’-(beta-D-glucuronic acid)-5’-deoxy-5-fluorocytidine. Desmoulin F., Gilard V., Martino R., Malet-Martino M. Journal of Chromatography B 2003, 792, 323-332.

22. Metabolism of a novel nucleoside analogue, OGT 719, in the isolated perfused rat liver model, in rats, in tumour models and in patients. Desmoulin F., Gilard V., Malet-Martino M., Martino R., Molina C., Smith P. Xenobiotica 2003, 33, 289-303.

21. Metabolism of capecitabine, an oral fluorouracil prodrug: 19F NMR studies in animal models and human urine. Desmoulin F., Gilard V., Malet-Martino M., Martino R. Drug Metabolism and Disposition 2002, 30, 1221-1229.

20. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1) : a review. Malet-Martino M., Martino R. The Oncologist 2002, 7, 288-323.
(Article sélectionné pour faire partie du The Oncologist’s Continuing Medical Education (CME) on-line program)

19. The prodrugs of 5-fluorouracil. Malet-Martino M., Jolimaitre P., Martino R. Current Medicinal Chemistry - Anti-Cancer Agents 2 2002, 267-310.

18. Identification of new aqueous chemical degradation products of isophosphoramide mustard. Breil S., Martino R., Gilard V., Malet-Martino M., Niemeyer U. Journal of Pharmaceutical and Biomedical Analysis 2001, 25, 669-678.

17. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solution. Gilard V., Martino R., Malet-Martino M., Niemeyer U., Pohl J. Journal of Medicinal Chemistry 1999, 42, 2542-2560.

16. Characterization of choline compounds with in vitro 1H MRS for the discrimination of primary brain tumors. Sabatier J., Gilard V., Malet-Martino M., Ranjeva J.P., Terral C., Breil S., Delisle M.B., Manelfe C., Tremouler M., Berry I. Investigative Radiology 1999, 34, 230-235.

15. Urinary excretion of cyclophosphamide in humans determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Joqueviel C., Martino R., Gilard V., Malet-Martino M., Canal P., Niemeyer U. Drug Metabolism and Disposition 1998, 26, 418-428.   
(meilleur article paru dans Drug Metabolism and Disposition en 1998)
(Prix James R. Gillette de l’American Society for Pharmacology and Experimental Therapeutics).

14. The anticancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Arellano M., Malet-Martino M., Martino R., Gires P. British Journal of Cancer 1998, 77, 79-86.

13. 5-ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid, in the isolated perfused rat liver model. Arellano M., Malet-Martino M., Martino R., Spector T. British Journal of Cancer 1997, 76, 1170-1180.

12. Stability of commercial formulations and aqueous solutions of ifosfamide. A reply. Gilard V., Martino R., Malet-Martino M., Niemeyer U. Drug Metabolism and Disposition 1997, 25, 927-931.

11. A 13C NMR study of 2-13C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophos-phamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Joqueviel C., Malet-Martino M., Martino R. Cellular and Molecular Biology 1997, 43, 773-782.

10. Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide. Joqueviel C. Gilard V., Martino R. Malet-Martino M. Niemeyer U. Cancer Chemotherapy and Pharmacology 1997, 40, 391-399.

9. Chemical and biological evaluation of hydrolysis products of cyclophosphamide. Gilard V., Martino R., Malet-Martino M.C., Kutscher B., Muller A., Niemeyer U., Pohl J., Polymeropoulos E.E. Journal of Medicinal Chemistry 1994, 37, 3986-3993.

8. Determination of the urinary excretion of ifosfamide and all its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy. Gilard V., Malet-Martino M.C. De Forni M. Niemeyer U., Ader J.C. Martino R. Cancer Chemotherapy and Pharmacology 1993, 31, 387-394.

7. Cardiotoxicity of high-dose 5-fluorouracil continuous infusion: a prospective clinical study. De Forni M, Malet-Martino M.C., Jaillais P. Shubinski R.E., Bachaud J.M., Lemaire L., Canal P., Chevreau C., Carrie D., Soulie P., Roche H., Boudjema B., Mihura J., Martino R., Bernadet P., Bugat R. Journal of Clinical Oncology 1992, 10, 1795-1801. Lemaire L. Malet-Martino M.C., De Forni M., Martino R., Lasserre B. British Journal of Cancer 1992, 66, 119-127.

6. A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. Martino R., Crasnier F., Chouini-Lalanne N., Gilard V., Niemeyer U., De Forni M., Malet-Martino M.C. Journal of Pharmacology and Experimental Therapeutics 1992, 260, 1133-1144.

5. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche). Lemaire L., Malet-Martino M.C., Longo S., Martino R., De Forni M., Carton M. The Lancet 1991, 337, 560.

4. Direct 19F NMR spectroscopic observation of 5-fluorouracil metabolism in the isolated perfused mouse liver model. Cabanac S., Malet-Martino M.C., Bon M., Martino R., Nedelec J.F, Dimicoli J.L. NMR in Biomedicine 1988, 1, 113-120.

3. 19F NMR spectrometry evidence for bile acid conjugates of -fluoro--alanine as the main biliary metabolites of antineoplastic fluoropyrimidines in humans. Malet-Martino M.C., Bernadou J., Martino R., Armand J.P. Drug Metabolism and Disposition 1988, 16, 78-84.

2. Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance. Vialaneix J.P., Malet-Martino M.C., Hoffmann J.S., Pris J., Martino R. Drug Metabolism and Disposition 1987, 15, 718-724.

1. Evidence for the importance of 5'-deoxy-5-fluorouridine catabolism in humans from 19F nuclear magnetic resonance spectrometry. Malet-Martino M.C., Armand J.P., Lopez A., Bernadou J., Beteille J.P., Bon M., Martino R. Cancer Research 1986, 46, 2105-2112

Date de mise à jour 6 janvier 2016


en cours
Université Toulouse III - Paul Sabatier - 118 route de Narbonne 31062 TOULOUSE CEDEX 9 téléphone +33 (0)5 61 55 66 11
Université de Toulouse Université Toulouse III - Paul Sabatier